The PurpleLab®

Jared Safran

News

Higher SARS-COV-2 spike antibody levels are associated with reduced risk of subsequent symptomatic and severe COVID-19. Jin, Yue; Yang, Fei; Rank, Christopher; Letovsky, Stanley; Ramge, Peter and Jochum, Simon from Roche Information Solutions, Roche Diagnostics GmbH, Roche Diagnostics Solutions, and Roche Diagnostics International presented a poster during ISPOR 2024. The objective was to assess the…

Articles

Creating a holistic direct to consumer (DTC) and healthcare provider (HCP) marketing strategy from scratch is a demanding task, especially if you don’t have the clinical expertise to precisely identify the consumers or providers you should be targeting. We’re here to give you 5 simple steps to creating a holistic DTC and HCP targeting strategy…

News

PurpleLab® provides a real-world data [lab], accelerating the discovery and adoption of healthcare innovations. View where PurpleLab insights have been leveraged.  Healthcare IT News PurpleLab Introduced Alerts to Help Life Science Organizations Determine When to Engage with Physicians Read Now 6/9/2024 NBC News (Online) Popular Weight Loss Drugs Remain Out of Reach for Many Who…

Articles

This blog is part three in a series exploring the use of real-world evidence to produce meaningful insights in clinical pharma.  Health Economics and Outcomes Research (HEOR) is a field that determines the cost-effectiveness of drugs, medical devices and other healthcare interventions. It analyzes data from various sources to build evidence around the value of…

Articles

Open claims and closed claims data serve as vital tools for comprehending patients’ progress and engagements throughout their healthcare voyage. However, which data type proves most advantageous and under what circumstances? Whether the need is to assess the cost-effectiveness of a recently introduced medication or streamline clinical trial recruitment, both open claims data and closed…

Articles

As treatment options for patients are constantly evolving, staying ahead of the curve is critical for life science companies and physicians. But with so many options in the market, how can companies gain a competitive advantage with prescribers? By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes. PurpleLab®, a healthcare…

Case Studies

Analyzing real-world data (RWD) in pharmaceutical marketing has the power to unearth hidden trends and insights into the overall prescription landscape. However, accessing and compiling this data tends to be a resource-intensive process. This case study explores how PurpleLab’s Prescription Measurement Report empowered the marketing agency Deerfield to harness RWD insights effectively.   The Client Deerfield, a leading medical…

Articles

This blog is the fourth and final part in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  Of course, the right partner can help life sciences companies keenly focus on doing what they do best. PurpleLab® is a health-tech company driven by…

Articles

This blog is part three in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  Commercial teams at life sciences companies need to reinvent their go-to-market strategies. In doing so, however, they are apt to face a variety of challenges such as:…

Articles

This blog is part two in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  Life sciences companies are operating in a new world, one where new treatments are being developed at breakneck speed, which holds unprecedented promise for patients. However, this…

Articles

This blog is part one in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  The problem: Historical methodologies for targeting, marketing and commercial launch are no longer sufficient to ensure that those patients who could benefit the most from a new…